论文部分内容阅读
目的:观察阿托伐他汀联合氯吡格雷治疗短暂性脑缺血发作(TIA)的临床疗效,以及对患者血浆超敏C反应蛋白(hs-CRP)和脂蛋白相关磷脂酶A2(Lp-PLA2)的影响。方法:80例TIA患者根据住院号分为观察组与对照组,每组各40例。两组患者均予常规治疗;观察组在此基础上加用阿托伐他汀片20 mg,po qd,氯吡格雷片75 mg,po qd。两组疗程均为4周。观察两组疗效及药品不良反应,比较两组患者治疗前后血浆hs-CRP及Lp-PLA2水平。结果:治疗4周后,两组患者血浆hs-CRP、Lp-PLA2水平均较治疗前降低(P<0.05或P<0.01),且观察组降低幅度大于对照组(P<0.05);观察组总有效率高于对照组(P<0.05)。两组药品不良反应发生率比较,差异无统计学意义(P>0.05)。结论:阿托伐他汀联合氯吡格雷治疗TIA能提高临床疗效,且安全性好,其作用机制与降低血浆hs-CRP与Lp-PLA2水平密切相关。
Objective: To observe the clinical efficacy of atorvastatin combined with clopidogrel in the treatment of transient ischemic attack (TIA), and to evaluate the clinical effect of plasma hs-CRP and lipoprotein-associated phospholipase A2 (Lp-PLA2) )Impact. Methods: Eighty TIA patients were divided into observation group and control group according to their hospitalization numbers, 40 cases in each group. The patients in both groups were treated routinely. On the basis of the observation group, atorvastatin tablets 20 mg, po qd, clopidogrel tablets 75 mg, po qd were added. Two courses of treatment were 4 weeks. The curative effect and adverse drug reaction of the two groups were observed. The levels of plasma hs-CRP and Lp-PLA2 in both groups were compared before and after treatment. Results: After 4 weeks of treatment, the levels of plasma hs-CRP and Lp-PLA2 in both groups were lower than those before treatment (P <0.05 or P <0.01), and the decrease in the observation group was greater than that in the control group (P <0.05) The total effective rate was higher than that of the control group (P <0.05). There was no significant difference between the two groups in the incidence of adverse drug reactions (P> 0.05). Conclusion: Atorvastatin combined with clopidogrel in the treatment of TIA can improve the clinical efficacy and safety, its mechanism of action and reduce the plasma hs-CRP and Lp-PLA2 levels are closely related.